Eli Lilly To Explore MiNA's Small Activating RNA Technology
Milestones Could Total More Than $1bn
Executive Summary
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.